A review of life science events reported on this week by MedCity News:
Medtronic hypertension device tops Cleveland Clinic medical innovations. The device, which Medtronic acquired through its $800 million acquisition of Ardian earlier this year, is called the Symplicity Catheter System. It works via a process known as renal denervation, or ablation of the nerves that line the renal arteries, and could represent a way to control resistant hypertension without drugs.
Change of heart: Why Pozen now wants to partner its cardiovascular drug. “It really comes down to how we can maximize the asset,” Chief Commercial Officer Liz Cermak said in a conference call with analysts. “We’re a little company with a limited amount of resources.”
Case Western Reserve’s most promising med-tech startups. As director of the Coulter-Case Translational Research Partnership, Drummond is behind a $1 million fund that often invests in technologies spun out of Case. Drummond discusses a few spinoff companies, including next-generation insulin developer Thermalin Diabetes and stroke device start Swallowing Solutions.
Cleveland Clinic CEO: Comparative effectiveness will ‘chill’ innovation. Comparative effectiveness research, one of the key tenets of federal health reform, “seems good on first blush” but will have a chilling effect on medical innovation, Cleveland Clinic CEO Dr. Toby Cosgrove said.

Comments
Post a comment
No comments yet.
Post a Comment